Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus.

The Journal of clinical endocrinology and metabolism 20120901

Spanish COPD Guidelines (GesEPOC): pharmacological treatment of stable COPD. Spanish Society of Pulmonology and Thoracic Surgery.

Archivos de bronconeumologia 20120701

Superiority of PC-SOD to other anti-COPD drugs for elastase-induced emphysema and alteration in lung mechanics and respiratory function in mice.

American journal of physiology. Lung cellular and molecular physiology 20120615

Phosphodiesterase-4 inhibition as a therapeutic approach to treat capillary leakage in systemic inflammation.

The Journal of physiology 20120601

Physiological effects of roflumilast at rest and during exercise in COPD.

The European respiratory journal 20120501

Roflumilast enhances the renal protective effects of retinoids in an HIV-1 transgenic mouse model of rapidly progressive renal failure.

Kidney international 20120501

Can we cure HIV-1-associated nephropathy in transgenic mice?

Kidney international 20120501

Sensitive quantification of roflumilast and roflumilast N-oxide in human plasma by LC-MS/MS employing parallel chromatography and electrospray ionisation.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20120415

Additive anti-inflammatory effects of beta 2 adrenoceptor agonists or glucocorticosteroid with roflumilast in human peripheral blood mononuclear cells.

Pulmonary pharmacology & therapeutics 20120401

Roflumilast: a novel treatment for chronic obstructive pulmonary disease.

The Annals of pharmacotherapy 20120401

Roflumilast inhibits the release of chemokines and TNF-α from human lung macrophages stimulated with lipopolysaccharide.

British journal of pharmacology 20120301

Lack of involvement of type 7 phosphodiesterase in an experimental model of asthma.

The European respiratory journal 20120301

New drugs 2012 part I.

Nursing 20120301

Clinical Considerations for Roflumilast: A New Treatment for COPD.

The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists 20120301

Dual β2-adrenoceptor agonists-PDE4 inhibitors for the treatment of asthma and COPD.

Bioorganic & medicinal chemistry letters 20120215

Anti-asthmatic effect of ASP3258, a novel phosphodiesterase 4 inhibitor.

International immunopharmacology 20120101

Anti-neutrophilic inflammatory activity of ASP3258, a novel phosphodiesterase type 4 inhibitor.

International immunopharmacology 20120101

Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.

Clinical therapeutics 20120101

Combination of roflumilast with a beta-2 adrenergic receptor agonist inhibits proinflammatory and profibrotic mediator release from human lung fibroblasts.

Respiratory research 20120101

Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.

International journal of chronic obstructive pulmonary disease 20120101

Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol.

International journal of chronic obstructive pulmonary disease 20120101

Roflumilast--a phosphodiesterase-4 inhibitor licensed for add-on therapy in severe COPD.

Swiss medical weekly 20120101

LPS-induced lung inflammation in marmoset monkeys - an acute model for anti-inflammatory drug testing.

PloS one 20120101

[Current anti-inflammatory therapy in patients with chronic obstructive pulmonary disease].

Terapevticheskii arkhiv 20120101

Pharmacological validation of Trypanosoma brucei phosphodiesterases B1 and B2 as druggable targets for African sleeping sickness.

Journal of medicinal chemistry 20111208

Pharmacokinetic evaluation of roflumilast.

Expert opinion on drug metabolism & toxicology 20111201

[New goals in COPD treatment. From symptom control to prevention of exacerbations].

MMW Fortschritte der Medizin 20111201

Roflumilast in Asian patients with COPD: A randomized placebo-controlled trial.

Respirology (Carlton, Vic.) 20111101

[Phosphodiesterase-4 inhibitors: a new target in treatment of COPD].

Deutsche medizinische Wochenschrift (1946) 20111101

Synthesis and biological activity of pyrido[3',2':4,5]furo[3,2-d]pyrimidine derivatives as novel and potent phosphodiesterase type 4 inhibitors.

European journal of medicinal chemistry 20111001

Roflumilast with long-acting β2-agonists for COPD: influence of exacerbation history.

The European respiratory journal 20110901

PDE4-inhibitors: a novel, targeted therapy for obstructive airways disease.

Pulmonary pharmacology & therapeutics 20110801

The differential impact of PDE4 subtypes in human lung fibroblasts on cytokine-induced proliferation and myofibroblast conversion.

Journal of cellular physiology 20110801

Influence of renal impairment on the pharmacokinetics of oral roflumilast: an open-label, parallel-group, single-center study.

International journal of clinical pharmacology and therapeutics 20110801

Roflumilast (Daliresp) for COPD.

The Medical letter on drugs and therapeutics 20110725

Supra-therapeutic doses of roflumilast have no effect on cardiac repolarization in healthy subjects.

Expert opinion on drug safety 20110701

Study investigating pharmacokinetic interaction between theophylline and roflumilast in healthy adults.

International journal of clinical pharmacology and therapeutics 20110701

ASP3258, an orally active potent phosphodiesterase 4 inhibitor with low emetic activity.

International immunopharmacology 20110601

Lack of pharmacokinetic and pharmacodynamic interactions of roflumilast with (R, S)-warfarin in healthy adult subjects.

International journal of clinical pharmacology and therapeutics 20110601

Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.

The Cochrane database of systematic reviews 20110511

Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease.

British journal of pharmacology 20110501

Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide.

Journal of clinical pharmacology 20110401

No dose adjustment on coadministration of the PDE4 inhibitor roflumilast with a weak CYP3A, CYP1A2, and CYP2C19 inhibitor: an investigation using cimetidine.

Journal of clinical pharmacology 20110401

Roflumilast for severe COPD?

Drug and therapeutics bulletin 20110401

[COPD and diabetes mellitus. Does pulmonary medication modify blood glucose metabolism?].

MMW Fortschritte der Medizin 20110317

[Introduction].

Revista clinica espanola 20110301

[Phosphodiesterase-4 inhibitors: roflumilast].

Revista clinica espanola 20110301

[Pulmonary medicine. Two new drugs for the treatment of COPD].

Revue medicale suisse 20110119

Inhibition of cyclooxygenase-2 prevents adverse effects induced by phosphodiesterase type 4 inhibitors in rats.

British journal of pharmacology 20110101

High absolute bioavailability of the new oral phosphodiesterase-4 inhibitor roflumilast.

International journal of clinical pharmacology and therapeutics 20110101

Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.

Respiratory research 20110101

New therapeutic options in the management of COPD - focus on roflumilast.

International journal of chronic obstructive pulmonary disease 20110101

[New drugs in chronic obstructive pulmonary disease].

Pneumonologia i alergologia polska 20110101

No relevant cardiac, pharmacokinetic or safety interactions between roflumilast and inhaled formoterol in healthy subjects: an open-label, randomised, actively controlled study.

BMC clinical pharmacology 20110101

Reduce disease burden and improve lung function-roflumilast: approved for moderate to severe COPD: update for the clinical nurse specialist.

Clinical nurse specialist CNS 20110101

Roflumilast, indacaterol maleate, and abiraterone acetate.

Journal of the American Pharmacists Association : JAPhA 20110101

Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD.

Journal of medical economics 20110101

Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects.

Respiratory research 20110101

[A new alternative treatment in COPD: phosphodiesterase-4 inhibitors].

Tuberkuloz ve toraks 20110101

The use of roflumilast in COPD: a primary care perspective.

Primary care respiratory journal : journal of the General Practice Airways Group 20101201

Topical effects of roflumilast on 1-chloro-2,4-dinitrobenzene-induced atopic dermatitis-like skin lesions in NC/Nga mice.

Die Pharmazie 20101201

[Pharmacological profile of roflumilast].

Archivos de bronconeumologia 20101201

[Clinical profile of roflumilast].

Archivos de bronconeumologia 20101201

[Introduction. COPD treatment].

Archivos de bronconeumologia 20101201

Roflumilast for COPD.

Drugs of today (Barcelona, Spain : 1998) 20101101

Roflumilast for the treatment of chronic obstructive pulmonary disease.

Expert review of respiratory medicine 20101001

Roflumilast.

Nature reviews. Drug discovery 20101001

Roflumilast: clinical benefit in patients suffering from COPD.

The clinical respiratory journal 20101001

Chronopharmacology of roflumilast: a comparative pharmacokinetic study of morning versus evening administration in healthy adults.

Chronobiology international 20101001

Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model.

Clinical pharmacokinetics 20100901

Roflumilast: in chronic obstructive pulmonary disease.

Drugs 20100820

The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.

Pulmonary pharmacology & therapeutics 20100801

Exposing rodents to a combination of tobacco smoke and lipopolysaccharide results in an exaggerated inflammatory response in the lung.

British journal of pharmacology 20100801

The divergent opinions of regulatory authorities on roflumilast are puzzling but we need new drugs for treating chronic obstructive pulmonary disease.

Therapeutic advances in respiratory disease 20100801

[Roflumilast: a new approach to therapy of chronic obstructive pulmonary disease].

Medizinische Monatsschrift fur Pharmazeuten 20100701

Effect of cyclic AMP-elevating agents on airway ciliary beat frequency in central and lateral airways in rat precision-cut lung slices.

European journal of pharmacology 20100610

[Diseases of the lung and air passages 2010].

Deutsche medizinische Wochenschrift (1946) 20100601

Water-soluble PDE4 inhibitors for the treatment of dry eye.

Bioorganic & medicinal chemistry letters 20100501

New evidence in pulmonary and preventive medicine.

Internal and emergency medicine 20100401

Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor.

COPD 20100401

Roflumilast in chronic obstructive pulmonary disease: evidence from large trials.

Expert opinion on pharmacotherapy 20100201

The role of the phosphodiesterase-4 inhibitor, roflumilast, in chronic obstructive pulmonary disease.

Polskie Archiwum Medycyny Wewnetrznej 20100101

Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.

Drug design, development and therapy 20100101

PDE4 inhibitors: a review of current developments (2005 - 2009).

Expert opinion on therapeutic patents 20091101

Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects.

British journal of clinical pharmacology 20091001

The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.

The Journal of pharmacology and experimental therapeutics 20090901

Phosphodiesterase-4 inhibition in COPD.

Lancet (London, England) 20090829

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.

Lancet (London, England) 20090829

Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials.

Lancet (London, England) 20090829

Effects of roflumilast, a phosphodiesterase-4 inhibitor, on hypoxia- and monocrotaline-induced pulmonary hypertension in rats.

The Journal of pharmacology and experimental therapeutics 20090701

PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts.

American journal of physiology. Lung cellular and molecular physiology 20090601

Roflumilast increases Clara cell secretory protein in cigarette smoke-exposed mice.

COPD 20090601

The targeted oral, once-daily phosphodiesterase 4 inhibitor roflumilast and the leukotriene receptor antagonist montelukast do not exhibit significant pharmacokinetic interactions.

Journal of clinical pharmacology 20090401

Effect of repeated dose of erythromycin on the pharmacokinetics of roflumilast and roflumilast N-oxide.

International journal of clinical pharmacology and therapeutics 20090401

Discovery of (S)-N-[2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl] acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor.

Journal of medicinal chemistry 20090326

Quinolines as a novel structural class of potent and selective PDE4 inhibitors: optimisation for oral administration.

Bioorganic & medicinal chemistry letters 20090301

Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury.

British journal of pharmacology 20090201

Effects of the phosphodiesterase type 4 inhibitor roflumilast on early and late allergic response and airway hyperresponsiveness in Aspergillus-fumigatus-sensitized mice.

Pharmacology 20090101

Effect of single and repeated doses of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-oxide.

Journal of clinical pharmacology 20081101

Curative effects of phosphodiesterase 4 inhibitors cilomilast, roflumilast, and rolipram in dermatitis mouse model.

Journal of dermatological science 20080901

Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: a randomized placebo-controlled trial.

Pulmonary pharmacology & therapeutics 20080801

Anti-inflammatory modulation of chronic airway inflammation in the murine house dust mite model.

Pulmonary pharmacology & therapeutics 20080801

Development and characterisation of a novel and rapid lung eosinophil influx model in the rat.

Pulmonary pharmacology & therapeutics 20080801

Single-dose pharmacokinetics of roflumilast in children and adolescents.

Journal of clinical pharmacology 20080801

Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors.

Bioorganic & medicinal chemistry letters 20080715

The selective MMP-12 inhibitor, AS111793 reduces airway inflammation in mice exposed to cigarette smoke.

British journal of pharmacology 20080701

PDE4 inhibitor, roflumilast protects cardiomyocytes against NO-induced apoptosis via activation of PKA and Epac dual pathways.

Cellular signalling 20080501

Suppression of cytokine expression by roflumilast and dexamethasone in a model of chronic asthma.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 20080501

Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma.

Expert opinion on investigational drugs 20080501

Inhibition of phosphodiesterase type 4 decreases stress-induced defecation in rats and mice.

Pharmacology 20080101

Effect of roflumilast on inflammatory cells in the lungs of cigarette smoke-exposed mice.

BMC pulmonary medicine 20080101

[Selective phosphodiesterase-4 (PDE-4) inhibitors in COPD].

Tuberkuloz ve toraks 20080101

Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD.

Thorax 20071201

Treating COPD with PDE 4 inhibitors.

International journal of chronic obstructive pulmonary disease 20071201

Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats.

European journal of pharmacology 20071001

Roflumilast inhibits leukocyte-endothelial cell interactions, expression of adhesion molecules and microvascular permeability.

British journal of pharmacology 20071001

Phosphodiesterase 4 inhibitors augment levels of glucocorticoid receptor in B cell chronic lymphocytic leukemia but not in normal circulating hematopoietic cells.

Clinical cancer research : an official journal of the American Association for Cancer Research 20070815

The oral, once-daily phosphodiesterase 4 inhibitor roflumilast lacks relevant pharmacokinetic interactions with inhaled budesonide.

Journal of clinical pharmacology 20070801

Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease.

American journal of respiratory and critical care medicine 20070715

L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition.

Biochemical pharmacology 20070615

PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast.

International journal of chronic obstructive pulmonary disease 20070601

Magnesium hydroxide/aluminium hydroxide-containing antacid does not affect the pharmacokinetics of the targeted phosphodiesterase 4 inhibitor roflumilast.

Journal of clinical pharmacology 20070501

A reporter gene assay for screening of PDE4 subtype selective inhibitors.

Biochemical and biophysical research communications 20070427

Lack of a pharmacokinetic interaction between steady-state roflumilast and single-dose midazolam in healthy subjects.

British journal of clinical pharmacology 20070301

Roflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsiveness after allergen challenge.

Respiration; international review of thoracic diseases 20070101

Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor.

Journal of clinical pharmacology 20070101

Steady-state pharmacokinetics of roflumilast and roflumilast N-oxide in patients with mild and moderate liver cirrhosis.

Clinical pharmacokinetics 20070101

Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide.

Clinical pharmacokinetics 20070101

A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease.

PharmacoEconomics 20070101

Evaluation of PDE4 inhibition for COPD.

International journal of chronic obstructive pulmonary disease 20061201

Roflumilast, a once-daily oral phosphodiesterase 4 inhibitor, lacks relevant pharmacokinetic interactions with inhaled salbutamol when co-administered in healthy subjects.

International journal of clinical pharmacology and therapeutics 20061101

Phosphodiesterase type 4 inhibitors cause proinflammatory effects in vivo.

The Journal of pharmacology and experimental therapeutics 20061001

Investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjects.

Journal of clinical pharmacology 20061001

Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of respiratory disease.

Expert opinion on investigational drugs 20060901

A phosphodiesterase 4 inhibitor inhibits matrix protein deposition in airways in vitro.

The Journal of allergy and clinical immunology 20060901

The potential role of roflumilast: the new phosphodiesterase-4 inhibitor.

The Annals of pharmacotherapy 20060601

Roflumilast for the treatment of chronic obstructive pulmonary disease.

Current opinion in investigational drugs (London, England : 2000) 20060501

Phosphodiesterase type 4 inhibitors for asthma: a real breakthrough or just expensive theophylline?

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20060501

Efficacy and safety of roflumilast in the treatment of asthma.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 20060501

Phosphodiesterase inhibitors in airways disease.

European journal of pharmacology 20060308

Phosphodiesterase 4 inhibition with roflumilast: a new approach to pulmonary disease.

Expert opinion on pharmacotherapy 20060301

Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.

Pulmonary pharmacology & therapeutics 20060101

Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma.

Allergy 20060101

Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells.

Respiratory research 20060101

Phosphodiesterase 4 inhibitors for the treatment of asthma and COPD.

Current medicinal chemistry 20060101

Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation.

The Journal of pharmacology and experimental therapeutics 20051201

The inhibitory effects of roflumilast on lipopolysaccharide-induced nitric oxide production in RAW264.7 cells are mediated by heme oxygenase-1 and its product carbon monoxide.

Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20051201

Roflumilast inhibition of pulmonary leukotriene production and bronchoconstriction in ovalbumin-sensitized and -challenged Guinea pigs.

The Journal of asthma : official journal of the Association for the Care of Asthma 20051201